US20020091158A1 - Composition for and method of treatment using triterpenoids - Google Patents

Composition for and method of treatment using triterpenoids Download PDF

Info

Publication number
US20020091158A1
US20020091158A1 US09/976,838 US97683801A US2002091158A1 US 20020091158 A1 US20020091158 A1 US 20020091158A1 US 97683801 A US97683801 A US 97683801A US 2002091158 A1 US2002091158 A1 US 2002091158A1
Authority
US
United States
Prior art keywords
och
lower alkyl
taken together
sarcoma
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/976,838
Inventor
Ornella Flore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/976,838 priority Critical patent/US20020091158A1/en
Publication of US20020091158A1 publication Critical patent/US20020091158A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • AIDS Acquired Immunodeficiency Syndrome
  • AIDS is a disease of an acquired immunodeficiency syndrome in humans caused by HIV.
  • the first description of the disease was in 1981. Its causative agent, HIV, was discovered in 1983. As of 1993 it is estimated that about 13 million people were infected with HIV worldwide and this number has increased to about 21 million in 1996. See B. Jasny, Science, 260(5112), 1219 (1993) and P. Piot, Science, 272(5270), 1855 (1996).
  • AIDS was first diagnosed in male homosexuals who exhibited a variety of infections of fungal ( Candida albicans ), protozoal ( Pneumocystis carinii ), and viral ( Herpes zoster ) origin. Many of these individuals also had an increased incidence of kaposi sarcoma and lymphoma. They had a depressed T helper/T suppressor lymphocyte cell ratio and an absence of delayed hypersensitivity responses. Collectively, these observations suggested a deficiency in cell-mediated immunity.
  • HIV-1 human immunodeficiency virus
  • HIV possesses an envelope glycoprotein (gp120) that has a high affinity for the CD.sub.4 receptor on T helper cells and other target cells.
  • T helper cells include bone marrow stem cells, macrophages, endothelial cells, glial cells, lymph node, dendritic cells, bowel enterochromaffm cells, cervical eptithlium and possibly Langerhans cells.
  • T helper cells include bone marrow stem cells, macrophages, endothelial cells, glial cells, lymph node, dendritic cells, bowel enterochromaffm cells, cervical eptithlium and possibly Langerhans cells.
  • T-helper cells it is the effects of HIV on T-helper cells that are the best known.
  • the infectious process begins when the virus penetrates the body and enters the blood stream.
  • Binding of HIV to CD.sub.4 target cells involves interaction of the external envelope glycoprotein molecule gp120 with the CD.sub.4 molecule, although other cell receptors may be involved.
  • the virus next enters the target cell, or is internalized, through fusion of the viral envelope with the target cell membrane. Through this fusion, the virus loses its coat, and releases its RNA core and reverse transcriptase enzyme into the host cell cytoplasm.
  • the HIV reverse transcriptase enzyme copies the RNA message producing first a single-stranded, and then a double-stranded, DNA (circular complementary DNA). This newly formed double-stranded DNA becomes incorporated into the host chromosomal DNA once it enters the host cell nucleus. This incorporated viral DNA may remain dormant or, upon activation, will produce viral messenger RNA (mRNA).
  • mRNA viral messenger RNA
  • the viral mRNA codes for proteins that are important in viral replication. Glycoprotein will then envelop the RNA genome resulting in the production of infectious viral particles; completed viral particles are then released to infect other cells.
  • AIDS vaccine (Salk's vaccine) has been tested and several proteins which are chemokines from CD8 have been discovered to act as HIV suppressors.
  • HIV viruses continue to mutate and become resistant to existing drugs such as the reverse transcriptase inhibitors and protease inhibitors.
  • a therapy of using two (2) or three (3) anti-HIV drugs in combination has been found effective in significantly lowering the HIV loads in AIDS patients.
  • the results have been promising, however the virus continues to develop resistance to the drugs and the long-term outcome (survival and cure rates) is still unknown.
  • the medical communities throughout the world continue to search for drugs that can prevent HIV infections, treat HIV carriers to prevent them from progressing to full-blown deadly AIDS, and treat the AIDS patient.
  • Kaposi's sarcoma is the most common neoplasm occurring in persons with acquired immunodeficiency syndrome (AIDS). Approximately 15-20% of AIDS patients develop this neoplasm which rarely occurs in non-AIDS infected individuals. Epidemiologic evidence suggests that AIDS-associated Kaposi's sarcoma(AIDS-KS)may have an infectious etiology.
  • Kaposi's sarcoma-associated herpesvirus KSHV/HHV8 is a new human herpesvirus found in all KS lesions and considered the infectious agent.
  • Kaposi's sarcoma is uncommon among adult AIDS patients infected through heterosexual or parenteral HIV transmission, or among pediatric AIDS parenteral HIV transmission, or among pediatric AIDS patients infected through vertical HIV transmission.
  • Agents previously suspected of causing Kaposi's sarcoma include cytomegalovirus, hepatitis B virus, human papillomavirus, Epstein-Barr virus, human herpesvirus 6, human immunodeficiency virus (HIV), and Mycoplasma penetrans.
  • Non-infectious environmental agents such as nitrite inhalants
  • nitrite inhalants also have been proposed to play a role in Kaposi's sarcoma tumorigenesis.
  • Extensive investigations have not demonstrated an etiologic association between any of these agents and AIDS-KS.
  • Herpesviruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) are a family of large double stranded DNA-containing viruses many members of which are important human pathogens.
  • KSHV Kaposi's sarcoma-associated herpesvirus
  • a ubiquitous property of the herpesviruses is their capacity to cause both acute lytic(productive) and latent infections in the human host, each of which is characterized by marked differences in viral transcription, DNA replication and in DNA structure.
  • Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV 8)
  • KSHV Kaposi's sarcoma-associated herpesvirus
  • HHV 8 human herpesvirus 8
  • AIDS related epidemic
  • European sporadic
  • Transplant-associated iatrogenic
  • African endemic
  • This virus is generally absent from normal control tissues, it is present in the vast majority of AIDS- as well as non-AIDS- related KS lesions, suggesting that it is not simply an opportunistic infection in HIV-infected patients.
  • Chang Y et al Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
  • KSHV is consistently present in a specific type of non-Hodgkin's lymphoma (NHL), frequently, not exclusively, occurring in patients with AIDS, namely the primary effusion lymphomas (PELs), also called body cavity-based lymphomas (BCBLs).
  • PELs primary effusion lymphomas
  • BCBLs body cavity-based lymphomas
  • KSHV is also present in a significant proportion of cases of multicentric Castleman's disease, a poorly understood disorder characterized by generalized lymphadenopathies and immune disregulation.
  • Soulier J et al Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1275-1280, 1995.
  • Recently, the presence of KSHV in bone marrow dendritic cells of all patients with multiple myeloma has been reported.
  • Rettig M B et al Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-1854, 1997. While this last finding remains controversial, it raises the possibility of involvement of KSHV in a very frequent type of cancer affecting non-immunosuppressed individuals.
  • KSHV as all other herpesvirus, has a litic and a latent cycle. Only a few antiviral agents have been used for activity against KSHV.
  • TPA phorbol ester
  • the present invention relates to the use of a triterpenoid preferably a Glycyrrhizic acid (Glycyrrhizin) to inhibit the transcription of viral latent genes and the consequential viral latent cycle at doses that do not affect the uninfected cells.
  • a triterpenoid preferably a Glycyrrhizic acid (Glycyrrhizin) to inhibit the transcription of viral latent genes and the consequential viral latent cycle at doses that do not affect the uninfected cells.
  • Glycyrrhizic acid and derivatives the KSHV infected cells are completely killed six days after treatment.
  • FIG. 1 shows the effect of Glycyrrhizic acid on BJAB cells growth curve.
  • FIG. 2 shows the effect of Glycyrrhizic acid on BC-3 cells growth curve.
  • FIG. 3 shows Northern Blot of mRNA extracted from BJA-B and BC-3 cells after six days treatment.
  • FIG. 4 demonstrates the effect of glycyrrhizic acid on BC-1 cells growth curve.
  • FIG. 5 demonstrates the effect of glycyrrhizic acid on BC-2 cells growth curve
  • FIG. 6 shows the structural formula of the triterpenoid acid of the present invention.
  • FIG. 7 shows the structural formula of glycyrrhizic acid.
  • FIG. 8 shows the structural formula of glycyrrhetinic acid which when combined with two molecules of glucuronic acid forms glycyrrhizic acid.
  • FIG. 9 shows a further example of a triterpenoid acid derivatives of the present invention.
  • FIG. 10 shows an immunofluorence assay of BC-3 cells treated and untreated with a triterpenoid acid derivative of the present invention.
  • the present invention is directed to triterpenoid acid derivatives that exhibit pharmacophobic activities for the treatment of Kaposi's sarcoma (KSHV) preferably glycyrrhizic acid and its salts.
  • KSHV Kaposi's sarcoma
  • Examples of triterpenoids of the type useful in the present invention include those disclosed in U.S. Pat. No. 5,837,690 the disclosure of which are incorporated herein by reference.
  • FIG. 4 shows the structural formula for the triterpenoid acid of the present invention
  • FIG. 7 shows a further example of a triterpenoid acid derivative of the present invention wherein:
  • M 1 Na. + , K + , Mg ++ , Ca ++ ions
  • R 2 ⁇ CH 2 OR 1 or CH 3 ;
  • R 3 ⁇ H, CH 3 , lower alkyl, COY, CH 2 OH, CH 2 OCH 2 CH ⁇ CH 2 , CH 2 OSO-- 3 M 1 ;
  • R 5 and R 6 ⁇ H, R 1 or taken together to form a 5 or 6 membered carbocyclic ring;
  • Glycyrrhizin as used herein to denote glycyrrhizinic acid or a salt thereof, is a well-known substance as effective ingredient of Licorice used heretofore as medicine or sweetener.
  • isolated and refined glycyrrhizin is used widely in many fields of application and, especially, free acids, as well as sodium, potassium and ammonium salts including acidic salts of glycyrrhizin are used most widely or studied for their properties, all of these substances exhibiting marked sweetness and various pharmaceutical activities.
  • Glycyrrhizic acid (Glycyrrhizin) (FIG. 5) consists of one molecule of glycyrrhetinic acid (FIG. 6) and two molecules of glucuronic acid. Glycyrrhizic acid is freely soluble in hot water and alcohol. Ammonium glycyrrhizinate pentahydrate is soluble in ammonia water, ethanol, glacial acetic acid.
  • Glycyrrhizic acid (Glycyrrhizin) derivatives for Na+, K+ and triterpenoids compounds, which would work on viral inhibition, can be dissolved in chloroform, dioxane, alcohol, pyridine, acetic acid and most organic solvents.
  • the active part of the compound is believed to be the triterpenoid part (FIG. 4) (without the glucuronic acid) which is similar to steroids. Indeed this portion has an antinflammatory and antiulcerative activity. All derivatives without the glucuronic part have an antinflammatory activity.
  • the two molecules of glucuronic acid make the compound more hydrosoluble and rich in negative charges, it becomes less toxic but also less active if it's used at the same concentration.
  • compositions of the present invention can be administered to a patient by intravenous or parenteral injection, topical application, etc., in an amount to prevent or treat the Kaposi's sarcoma (KSHV).
  • KSHV Kaposi's sarcoma
  • the triterpenoid acid derivatives compounds of the invention can be administered to a subject in need thereof to treat the subject by either prophylactically preventing disease or relieving it after it has begun.
  • the invention compounds are preferably administered with a pharmaceutically acceptable carrier, the nature of the carrier dependant on the chemical properties of the compounds, including solubility properties, and/or the mode of administration. For example, if oral administration is desired, a solid carrier may be selected, and for I.V. administration a liquid salt solution carrier may be used.
  • the formulation of choice can be accomplished using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like.
  • Oral compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders. Particularly useful is the administration of the invention compounds directly in transdermal formulations with permeation enhancers such as DMSO.
  • Other topical formulations can be administered to treat certain disease indications.
  • the compounds of the instant invention will contain from less than 1% to about 95% of the active ingredient, preferably about 10% to about 50%.
  • the frequency of administration will be determined by the care given based on the responsiveness of the patient.
  • Other effective dosages can be readily determined by one of ordinary skill in the art through routine trials establishing dose response curves.
  • Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function.
  • Diluents such as water, aqueous saline or other known substances can be employed with the subject invention.
  • the nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride.
  • a surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.
  • the compounds of the instant invention may also be administered as injectables.
  • injectable compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
  • the preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.
  • the compounds of the present invention can be mixed with compatible, pharmaceutically acceptable excipients.
  • compositions or formulation to be administered will, in any event, contain a quantity of the compound adequate to achieve the desired state in the subject being treated.
  • the various compounds of the present invention can be used by themselves or in combination with pharmaceutically acceptable excipient materials as described above.
  • the glycyrrhizic acid or derivative can be administered orally, parenterally or through intravenous injections.
  • the preferred dose range is 2.5 mg to 50 mg/kg.
  • a preferred injection medium is water containing suitable stabilizers, solubilizers and/or buffers.
  • suitable dosage forms are creams, ointments and medicated plasters.
  • Glycyrrhizic salt preparations can be dissolved in water or phosphate buffer and neutralized with NaOh.
  • the Glycyrrhizic acid (as ammonium salt supplied by Sigma) is dissolved in 25% of ethanol at 100 mM and adjusted to pH 6.8 with 1 N sodium hydroxide.
  • the maximum inhibition activity with no effect on cell cycle is achieved with 4 mM, the dose-dependent range is within 2mM to 5mM.
  • BC-3 is a cell line established from a HIV negative patient with a primary effusion lymphoma. See Arvanitakis L, et al Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88:2648-2654, 1996. The cells are latently KSHV-infected, but lacks EBV, and can be induced to enter lytic replication and viral production by treatment with TPA or with butyrate. BC-3 has an intact KSHV genome and is suitable for the isolation and study of KSHV.
  • BJA-B is an Epstein-Barr virus (EBV)-negative lymphoblastoid cell line established from an African Burkift's lymphoma, KSHV negative cell line. See Menezes J, et al, Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 1975 Jul; 22 (4): 276-84. These cells are used as controls. Cells are cultured at concentration of 4 ⁇ 10 5 /ml in RPMI with 20% of fetal calf serum in the presence or absence of different drug concentrations.
  • EBV Epstein-Barr virus
  • BC-1 and BC-2 are cell lines established from two different HIV positive patients with non-Hodgkins lymphoma, specifically body cavity-based lymphomas.
  • the cells are KSHV/EBV-infected and can be induced to enter lytic replication and viral production by treatment with TPA or with butyrate. These cells have an intact KSHV and EBV genomes and are ideal for KSHV and EBV isolation and study.(Cesarman, E. et al., Blood 1995 Oct.;86(7):2708-14.
  • FIG. 1 shows the effect of Glycyrrhizic acid on BJAB cells growth curve.
  • Cells are treated for six days with alcohol 0.5% and 1%, Glycyrrhizic acid 2 mM and 4 mM in alcohol 0.5% and 1% respectively.
  • Glycyrrhizic acid has no effect on the cells proliferation.
  • FIG. 2 shows the effect of Glycyrrhizic acid on BC-3 cells growth curve.
  • the cells are treated for six days with alcohol 0.5% and 1%, Glycyrrhizic acid 2 mM and 4 mM in alcohol 0.5% and 1% respectively.
  • Cells growth is 50% inhibited by Glycyrrhizic acid 2 mM, while treatment with Glycyrrhizic acid 4 mM determines cell death.
  • FIG. 3 shows Northern Blot of mRNA extracted from BJA-B and BC-3 cells after six days treatment.
  • probes used On the left side are indicated the probes used. On the right side are indicated the size of the transcripts. All probes correspond to viral latent genes, except the human b actin which is used as a quantitative control to measure the transcription of total cellular mRNA.
  • Lanes 1-5 are the BJA-B cells which are not infected by KSHV, therefore they are negative, except for the b actin, which shows that the transcription of total cellular mRNA is not inhibited by the treatment with Glycyrrhizic acid.
  • Lane 6 is the positive control. Glycyrrhizic acid 2 mM does not show any effect on the viral latent genes transcription (lane 7), while at 4 mM the transcription is almost totally inhibited (lane 8). Treatment with alcohol 1%, which is the percentage present in the Glycyrrhizic acid 4 mM, does not affect the transcript products. This result excludes the possibility that the inhibition is due to alcohol toxicity. Equal presence of ⁇ actin in all samples confirms that the compound does not have any effect on cellular mRNA.
  • FIGS. 4 and 5 demonstrate the effect of glycyrrhizic acid on BC-1 (FIG. 4) and BC-2 (FIG. 5) cells growth curve.
  • the cells are treated for six days with alcohol 1%, glycyrrhizic acid 2 mM (control), glycyrrhizic acid 3 mM and 4 mM in alcohol 0.5%, 0.75% and 1% respectively.
  • Cells growth decreased 80% using glycyrrhizic acid 4 mM.
  • cytospin preparations of KSHV—infected endothelial cells were fixed with methanol/acetone (1:1, vol/vol) solution at ⁇ 20° C. for 15 min., and then stained as described by Kedes et al. with sera from three different KS patients, diluted 1:40 in master block (MB) containing PBS supplemented with 1% glycine, 2% BSA, 10% rabbit serum and 1% (wt/vol) HeLa cell sonicate.
  • Secondary antibody FITC-conjugated F(ab′) 2 fragment of rabbit antihuman IgG (DAKO, Carpinteria, Calif.) diluted 1:40 in MB was applied.
  • FIG. 10 shows an immunofluorence assay of BC-3 cells where panel A depicts BC-3 cells stained with KS patient serum. Panel B shows BC-3 cells stained with Dapi to localize the nuclei. In panel C the BC-3 cells have been treated with glycyrrhizic acid 4 mM and stained with KS patient serum. In panel D BC-3 cells have been treated with glycyrrhizic acid 4 mM and stained with Dapi to localize the nuclei. Kaposi's Sarcoma patient serum is used primary antibody to stain the KSHV latent antigens. The treatment with glycyrrhizic acid 4 mM inhibits the expression of latent viral antigens as demonstrated in panel C. As can be seen in this panel, speckled nuclear stainings typical of positive infected cells disappears after the treatment with glycyrrhizic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for treating Kaposi's sarcoma and Epstein Barr virus using a a therapeutic derivative of a triterpenoid acid and derivatives thereof are disclosed,

Description

    BACKGROUND OF THE INVENTION
  • Acquired Immunodeficiency Syndrome (AIDS) is one of the most significant infections to appear in recent history. This epidemic is not confined to a single segment of the population nor is its spread blocked by natural barriers or international boundaries. Millions have died in Africa and many more individuals are infected worldwide. In the United States more than 100,000 people have died and at least 1 million more are presently infected with the virus. Although there are some new drug treatments that are currently available for treating the disease, this pandemic shows no signs of abating. [0001]
  • AIDS is a disease of an acquired immunodeficiency syndrome in humans caused by HIV. The first description of the disease was in 1981. Its causative agent, HIV, was discovered in 1983. As of 1993 it is estimated that about 13 million people were infected with HIV worldwide and this number has increased to about 21 million in 1996. See B. Jasny, Science, 260(5112), 1219 (1993) and P. Piot, Science, 272(5270), 1855 (1996). [0002]
  • AIDS was first diagnosed in male homosexuals who exhibited a variety of infections of fungal ([0003] Candida albicans), protozoal (Pneumocystis carinii), and viral (Herpes zoster) origin. Many of these individuals also had an increased incidence of kaposi sarcoma and lymphoma. They had a depressed T helper/T suppressor lymphocyte cell ratio and an absence of delayed hypersensitivity responses. Collectively, these observations suggested a deficiency in cell-mediated immunity.
  • The causative agent in AIDS is an RNA retrovirus called the human immunodeficiency virus (HIV-1 or HIV-2). HIV possesses an envelope glycoprotein (gp120) that has a high affinity for the CD.sub.4 receptor on T helper cells and other target cells. These other target cells include bone marrow stem cells, macrophages, endothelial cells, glial cells, lymph node, dendritic cells, bowel enterochromaffm cells, cervical eptithlium and possibly Langerhans cells. However, it is the effects of HIV on T-helper cells that are the best known. The infectious process begins when the virus penetrates the body and enters the blood stream. Binding of HIV to CD.sub.4 target cells involves interaction of the external envelope glycoprotein molecule gp120 with the CD.sub.4 molecule, although other cell receptors may be involved. The virus next enters the target cell, or is internalized, through fusion of the viral envelope with the target cell membrane. Through this fusion, the virus loses its coat, and releases its RNA core and reverse transcriptase enzyme into the host cell cytoplasm. [0004]
  • The HIV reverse transcriptase enzyme copies the RNA message producing first a single-stranded, and then a double-stranded, DNA (circular complementary DNA). This newly formed double-stranded DNA becomes incorporated into the host chromosomal DNA once it enters the host cell nucleus. This incorporated viral DNA may remain dormant or, upon activation, will produce viral messenger RNA (mRNA). The viral mRNA codes for proteins that are important in viral replication. Glycoprotein will then envelop the RNA genome resulting in the production of infectious viral particles; completed viral particles are then released to infect other cells. [0005]
  • In the efforts to combat the disease several drugs have been approved by the FDA for treating this disease, including azidovudine (AZT), didanosine (dideoxyinosine, ddI), d4T, zalcitabine (dideoxycytosine, ddC), nevirapine, lamivudine (epivir, 3TC), saquinavir (Invirase), ritonavir (Norvir), indinavir (Crixivan), and delavirdine (Rescriptor). See M. I. Johnston & D. F. Hoth, Science, 260(5112), 1286-1293 (1993) and D. D. Richman, Science, 272(5270), 1886-1888 (1996). [0006]
  • Many of the drugs currently approved for AIDS treatment utilize inhibition of viral proliferation and are viral reverse transcriptase inhibitors or viral protease inhibitors. Other protease inhibitors, such as nelfinavir and improved saquinavir, are either in development or close to approval. An AIDS vaccine (Salk's vaccine) has been tested and several proteins which are chemokines from CD8 have been discovered to act as HIV suppressors. [0007]
  • In addition to the synthetic nucleoside analogs, proteins, and antibodies noted above, several plants and substances derived from plants have been found to have in vitro anti-HIV activity, such as [0008] Lonicera japonica and Prunella vulgaris, and glycyrrhizin from Glycyrrhiza radix. See R. S. Chang & H. W. Yeung, Antiviral Research, 9, 163-175 (1988) and M. Ito, et al., Antiviral Research, 7, 127-137 (1987).
  • Despite all of the available pharmaceuticals for the treatment of HIV, there is still no cure for the deadly disease. HIV viruses continue to mutate and become resistant to existing drugs such as the reverse transcriptase inhibitors and protease inhibitors. Recently, a therapy of using two (2) or three (3) anti-HIV drugs in combination has been found effective in significantly lowering the HIV loads in AIDS patients. The results have been promising, however the virus continues to develop resistance to the drugs and the long-term outcome (survival and cure rates) is still unknown. Thus, the medical communities throughout the world continue to search for drugs that can prevent HIV infections, treat HIV carriers to prevent them from progressing to full-blown deadly AIDS, and treat the AIDS patient. [0009]
  • As noted above, many AIDS suffers are also afflicted with Kaposi's sarcoma. In fact, Kaposi's sarcoma is the most common neoplasm occurring in persons with acquired immunodeficiency syndrome (AIDS). Approximately 15-20% of AIDS patients develop this neoplasm which rarely occurs in non-AIDS infected individuals. Epidemiologic evidence suggests that AIDS-associated Kaposi's sarcoma(AIDS-KS)may have an infectious etiology. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is a new human herpesvirus found in all KS lesions and considered the infectious agent. Gay and bisexual AIDS patients are approximately twenty times more likely than hemophiliac AIDS patients to develop Kaposi's sarcoma, and Kaposi's sarcoma may be associated with specific sexual practices among gay men with AIDS. Kaposi's sarcoma is uncommon among adult AIDS patients infected through heterosexual or parenteral HIV transmission, or among pediatric AIDS parenteral HIV transmission, or among pediatric AIDS patients infected through vertical HIV transmission. Agents previously suspected of causing Kaposi's sarcoma include cytomegalovirus, hepatitis B virus, human papillomavirus, Epstein-Barr virus, [0010] human herpesvirus 6, human immunodeficiency virus (HIV), and Mycoplasma penetrans. Non-infectious environmental agents, such as nitrite inhalants, also have been proposed to play a role in Kaposi's sarcoma tumorigenesis. Extensive investigations, however, have not demonstrated an etiologic association between any of these agents and AIDS-KS.
  • Herpesviruses, such as Kaposi's sarcoma-associated herpesvirus (KSHV), are a family of large double stranded DNA-containing viruses many members of which are important human pathogens. A ubiquitous property of the herpesviruses is their capacity to cause both acute lytic(productive) and latent infections in the human host, each of which is characterized by marked differences in viral transcription, DNA replication and in DNA structure. [0011]
  • Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV 8), has been detected in all four clinical forms of Kaposi's sarcoma: AIDS related (epidemic), European (sporadic), Transplant-associated (iatrogenic) and African (endemic). While this virus is generally absent from normal control tissues, it is present in the vast majority of AIDS- as well as non-AIDS- related KS lesions, suggesting that it is not simply an opportunistic infection in HIV-infected patients. See Chang Y et al, Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994, Moore P S, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. N Engl J Med 332:1181-1185, 1995, Dupin N, et al, Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 345:761-762, 1995. [0012]
  • Furthermore, KSHV is consistently present in a specific type of non-Hodgkin's lymphoma (NHL), frequently, not exclusively, occurring in patients with AIDS, namely the primary effusion lymphomas (PELs), also called body cavity-based lymphomas (BCBLs). See Cesarman E, et al, Kaposi's Sarcoma-associated Herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Eng J Med 332:1186-1191, 1995, Nador R G, et al, Herpes-like DNA sequences in a body-cavity-based lymphoma in an HIV-negative patient (Letter to the Editor). N Engl J Med 333:943, 1995. [0013]
  • KSHV is also present in a significant proportion of cases of multicentric Castleman's disease, a poorly understood disorder characterized by generalized lymphadenopathies and immune disregulation. See Soulier J, et al Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1275-1280, 1995. Recently, the presence of KSHV in bone marrow dendritic cells of all patients with multiple myeloma has been reported. See Rettig M B, et al Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-1854, 1997. While this last finding remains controversial, it raises the possibility of involvement of KSHV in a very frequent type of cancer affecting non-immunosuppressed individuals. [0014]
  • KSHV, as all other herpesvirus, has a litic and a latent cycle. Only a few antiviral agents have been used for activity against KSHV. Several studies determined the effect of acyclovir, gancyclovir, foscarnet and cidofovir in their ability to prevent lytic replication of KSHV in response to phorbol ester (TPA) induction. See Kedes D H, D. G: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 99:2082-2086, 1997, Medveczky M M, et al In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. Aids 11:1327-1332, 1997, Costagliola D, et al Can anitviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'lnformation et de SOins de l'Immunodeficience Humaine (letter). Lancet 346:578, 1995, and Flore O, et al, Effect of DNA synthesis inhibitors on Kaposi's sarcoma-associated herpesvirus cyclin and major capsid protein gene expression. AIDS Res Hum Retroviruses vol.13, 14: 1229-1233,1997. [0015]
  • These drugs target only the litic viral replication, the latent viral infection cannot be controlled. Long-term treatment with these agents may be beneficial after the malignancy has developed, but is not resolutive. Once the treatment is interrupted the clinical reactivation can recur since the virus cannot be completely eliminated as the viral latent cycle is not affected. Accordingly,, there still remains a need for a drug which inhibits the latent cycle of KSHV/HHV8 and is free from deleterious side effects. [0016]
    • SUMMARY OF THE INVENTION
  • The present invention relates to the use of a triterpenoid preferably a Glycyrrhizic acid (Glycyrrhizin) to inhibit the transcription of viral latent genes and the consequential viral latent cycle at doses that do not affect the uninfected cells. Using Glycyrrhizic acid and derivatives, the KSHV infected cells are completely killed six days after treatment.[0017]
    • BRIEF DESCRIPTION
  • FIG. 1 shows the effect of Glycyrrhizic acid on BJAB cells growth curve. [0018]
  • FIG. 2 shows the effect of Glycyrrhizic acid on BC-3 cells growth curve. [0019]
  • FIG. 3 shows Northern Blot of mRNA extracted from BJA-B and BC-3 cells after six days treatment. [0020]
  • FIG. 4 demonstrates the effect of glycyrrhizic acid on BC-1 cells growth curve. [0021]
  • FIG. 5 demonstrates the effect of glycyrrhizic acid on BC-2 cells growth curve [0022]
  • FIG. 6 shows the structural formula of the triterpenoid acid of the present invention. [0023]
  • FIG. 7 shows the structural formula of glycyrrhizic acid. [0024]
  • FIG. 8 shows the structural formula of glycyrrhetinic acid which when combined with two molecules of glucuronic acid forms glycyrrhizic acid. [0025]
  • FIG. 9 shows a further example of a triterpenoid acid derivatives of the present invention. [0026]
  • FIG. 10 shows an immunofluorence assay of BC-3 cells treated and untreated with a triterpenoid acid derivative of the present invention.[0027]
    • DETAILED DESCRIPTION
  • The present invention is directed to triterpenoid acid derivatives that exhibit pharmacophobic activities for the treatment of Kaposi's sarcoma (KSHV) preferably glycyrrhizic acid and its salts. Examples of triterpenoids of the type useful in the present invention include those disclosed in U.S. Pat. No. 5,837,690 the disclosure of which are incorporated herein by reference. FIG. 4 shows the structural formula for the triterpenoid acid of the present invention and FIG. 7 shows a further example of a triterpenoid acid derivative of the present invention wherein: [0028]
  • Y═OR[0029] 1, NR1 2, O--M1;
  • R[0030] 1═H, LOWER ALKYL,
  • M[0031] 1=Na.+, K+, Mg++, Ca++ ions;
  • R[0032] 2═CH2OR1 or CH3;
  • R[0033] 3═H, CH3, lower alkyl, COY, CH2OH, CH2OCH2CH═CH2, CH2OSO--3M1;
  • Z═NR[0034] 1, NR.1Ac, NR1Bz, H, OCH3, lower alkyl, OH, SO3--M1, OCH2CH═CH2, OCH2CO2H or O-glucoside wherein a glucoside includes glucose, fucose, galactose, mannose, arabinose or xylose;
  • R[0035] 4═H, OH, SO3--M1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
  • or both R[0036] 4 taken together are oxo;
  • R[0037] 5 and R6═H, R1 or taken together to form a 5 or 6 membered carbocyclic ring;
  • X═O, S, NR[0038] 1 2
  • W═C═O, C═CR[0039] 1 2, CR1CR1 3, CR1—CR1 2OR1, COR1—CR1OR1 2, COR1CR1 2OR1, CR1CR1 2NR1 2, CR1CR1 2OCR1COY;
  • Glycyrrhizin, as used herein to denote glycyrrhizinic acid or a salt thereof, is a well-known substance as effective ingredient of Licorice used heretofore as medicine or sweetener. At present, isolated and refined glycyrrhizin is used widely in many fields of application and, especially, free acids, as well as sodium, potassium and ammonium salts including acidic salts of glycyrrhizin are used most widely or studied for their properties, all of these substances exhibiting marked sweetness and various pharmaceutical activities. [0040]
  • Glycyrrhizic acid (Glycyrrhizin) (FIG. 5) consists of one molecule of glycyrrhetinic acid (FIG. 6) and two molecules of glucuronic acid. Glycyrrhizic acid is freely soluble in hot water and alcohol. Ammonium glycyrrhizinate pentahydrate is soluble in ammonia water, ethanol, glacial acetic acid. Glycyrrhizic acid (Glycyrrhizin) derivatives for Na+, K+ and triterpenoids compounds, which would work on viral inhibition, can be dissolved in chloroform, dioxane, alcohol, pyridine, acetic acid and most organic solvents. The active part of the compound is believed to be the triterpenoid part (FIG. 4) (without the glucuronic acid) which is similar to steroids. Indeed this portion has an antinflammatory and antiulcerative activity. All derivatives without the glucuronic part have an antinflammatory activity. The two molecules of glucuronic acid make the compound more hydrosoluble and rich in negative charges, it becomes less toxic but also less active if it's used at the same concentration. [0041]
  • The compositions of the present invention can be administered to a patient by intravenous or parenteral injection, topical application, etc., in an amount to prevent or treat the Kaposi's sarcoma (KSHV).The triterpenoid acid derivatives compounds of the invention can be administered to a subject in need thereof to treat the subject by either prophylactically preventing disease or relieving it after it has begun. The invention compounds are preferably administered with a pharmaceutically acceptable carrier, the nature of the carrier dependant on the chemical properties of the compounds, including solubility properties, and/or the mode of administration. For example, if oral administration is desired, a solid carrier may be selected, and for I.V. administration a liquid salt solution carrier may be used. [0042]
  • The formulation of choice can be accomplished using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders. Particularly useful is the administration of the invention compounds directly in transdermal formulations with permeation enhancers such as DMSO. Other topical formulations can be administered to treat certain disease indications. [0043]
  • Typically, the compounds of the instant invention will contain from less than 1% to about 95% of the active ingredient, preferably about 10% to about 50%. Preferably, between about 10 mg and 50 mg will be administered to a child and between about 50 mg and 1000 mg will be administered to an adult. The frequency of administration will be determined by the care given based on the responsiveness of the patient. Other effective dosages can be readily determined by one of ordinary skill in the art through routine trials establishing dose response curves. [0044]
  • Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function. Diluents such as water, aqueous saline or other known substances can be employed with the subject invention. The nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa. [0045]
  • The compounds of the instant invention may also be administered as injectables. Typically, injectable compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles. The compounds of the present invention can be mixed with compatible, pharmaceutically acceptable excipients. [0046]
  • Certain methods of preparing dosage forms of the invention compounds are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 17th edition, 1985. The composition or formulation to be administered will, in any event, contain a quantity of the compound adequate to achieve the desired state in the subject being treated. The various compounds of the present invention can be used by themselves or in combination with pharmaceutically acceptable excipient materials as described above. [0047]
  • In a preferred embodiment the glycyrrhizic acid or derivative can be administered orally, parenterally or through intravenous injections. The preferred dose range is 2.5 mg to 50 mg/kg. A preferred injection medium is water containing suitable stabilizers, solubilizers and/or buffers. For topical treatment suitable dosage forms are creams, ointments and medicated plasters. Glycyrrhizic salt preparations can be dissolved in water or phosphate buffer and neutralized with NaOh. [0048]
    • Materials and Methods
  • The Glycyrrhizic acid (as ammonium salt supplied by Sigma) is dissolved in 25% of ethanol at 100 mM and adjusted to pH 6.8 with 1 N sodium hydroxide. The maximum inhibition activity with no effect on cell cycle is achieved with 4 mM, the dose-dependent range is within 2mM to 5mM. [0049]
    • Cell Culture Used for the Tests.
  • BC-3 is a cell line established from a HIV negative patient with a primary effusion lymphoma. See Arvanitakis L, et al Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88:2648-2654, 1996. The cells are latently KSHV-infected, but lacks EBV, and can be induced to enter lytic replication and viral production by treatment with TPA or with butyrate. BC-3 has an intact KSHV genome and is suitable for the isolation and study of KSHV. [0050]
  • BJA-B is an Epstein-Barr virus (EBV)-negative lymphoblastoid cell line established from an African Burkift's lymphoma, KSHV negative cell line. See Menezes J, et al, Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 1975 Jul; 22 (4): 276-84. These cells are used as controls. Cells are cultured at concentration of 4×10[0051] 5/ml in RPMI with 20% of fetal calf serum in the presence or absence of different drug concentrations.
  • BC-1 and BC-2 are cell lines established from two different HIV positive patients with non-Hodgkins lymphoma, specifically body cavity-based lymphomas. The cells are KSHV/EBV-infected and can be induced to enter lytic replication and viral production by treatment with TPA or with butyrate. These cells have an intact KSHV and EBV genomes and are ideal for KSHV and EBV isolation and study.(Cesarman, E. et al., Blood 1995 Oct.;86(7):2708-14. [0052]
    • RNA Extraction and Northern Blot Analysis to Measure the Transcription of Viral Genes
  • Total RNA was extracted using RNAzol B (Tel-Test Inc., Friendswood, Tex.) according to the manufacturer's instructions, and Poly A+RNA was selected with Poly A+ Tract kit (Promega, Madison, Wis.). To eliminate any contaminating DNA, the RNA samples were treated with 2 U RNAse free DNAse (Promega). [0053]
  • For Northern blot analysis, 1 μg/ml of each mRNA sample was electrophoresed in 1.5% formaldehyde agarose gel and then transferred to a Gene Screen nylon membrane (Du Pont, Boston, Mass.) overnight with 20×SSC. Filters were UV-cross-linked to fix the RNA and hybridized at 42° C. with probes obtained by PCR amplification of KSHV cyclin, v-FLIP and LANA (orf 73) genes (20) and labeled by [0054] 32P random priming (Amersham Life Science, Buckinghamshire, England). Human β-actin probe was used as a quantitative control to measure the total mRNA. Membranes were washed twice at room temperature and twice at 65° C. then exposed.
    • Results
  • FIG. 1 shows the effect of Glycyrrhizic acid on BJAB cells growth curve. Cells are treated for six days with alcohol 0.5% and 1%, [0055] Glycyrrhizic acid 2 mM and 4 mM in alcohol 0.5% and 1% respectively. Glycyrrhizic acid has no effect on the cells proliferation.
  • FIG. 2 shows the effect of Glycyrrhizic acid on BC-3 cells growth curve. The cells are treated for six days with alcohol 0.5% and 1%, [0056] Glycyrrhizic acid 2 mM and 4 mM in alcohol 0.5% and 1% respectively. Cells growth is 50% inhibited by Glycyrrhizic acid 2 mM, while treatment with Glycyrrhizic acid 4 mM determines cell death.
  • FIG. 3 shows Northern Blot of mRNA extracted from BJA-B and BC-3 cells after six days treatment. [0057]
  • Lane: 1 BJA-B [0058]
  • Lane: 2 BJA-B treated with [0059] Glycyrrhizic acid 2 mM
  • Lane: 3 BJA-B treated with [0060] Glycyrrhizic acid 4 mM
  • Lane:4-[0061]
  • Lane: 5 BJA-B treated with [0062] alcohol 1%
  • Lane: 6 BC-3 [0063]
  • Lane: 7 BC-3 treated with [0064] Glycyrrhizic acid 2 mM
  • Lane: 8 BC-3 treated with [0065] Glycyrrhizic acid 4 mM
  • Lane: 9-[0066]
  • Lane: 10 BC-3 treated with [0067] alcohol 1%
  • On the left side are indicated the probes used. On the right side are indicated the size of the transcripts. All probes correspond to viral latent genes, except the human b actin which is used as a quantitative control to measure the transcription of total cellular mRNA. [0068]
  • Lanes 1-5 are the BJA-B cells which are not infected by KSHV, therefore they are negative, except for the b actin, which shows that the transcription of total cellular mRNA is not inhibited by the treatment with Glycyrrhizic acid. [0069]
  • [0070] Lane 6 is the positive control. Glycyrrhizic acid 2 mM does not show any effect on the viral latent genes transcription (lane 7), while at 4 mM the transcription is almost totally inhibited (lane 8). Treatment with alcohol 1%, which is the percentage present in the Glycyrrhizic acid 4 mM, does not affect the transcript products. This result excludes the possibility that the inhibition is due to alcohol toxicity. Equal presence of β actin in all samples confirms that the compound does not have any effect on cellular mRNA.
  • FIGS. 4 and 5 demonstrate the effect of glycyrrhizic acid on BC-1 (FIG. 4) and BC-2 (FIG. 5) cells growth curve. The cells are treated for six days with [0071] alcohol 1%, glycyrrhizic acid 2 mM (control), glycyrrhizic acid 3 mM and 4 mM in alcohol 0.5%, 0.75% and 1% respectively. After 6 days treatment cells growth decreased 50% using glycyrrhizic acid 2 mM and glycyrrhizic acid 3 mM. Cells growth decreased 80% using glycyrrhizic acid 4 mM. These results demonstrate that glycyrrhizic acid is inhibiting the proliferation of the EBV/KSHV infected cells and suggests that the drug has an activity against the Epstein Barr virus.
    • Immunofluorence Assay of BC-3 Cells Immunofluorescence Assay (IFA)
  • To demonstrate the presence of latent KSHV antigens, cytospin preparations of KSHV—infected endothelial cells were fixed with methanol/acetone (1:1, vol/vol) solution at −20° C. for 15 min., and then stained as described by Kedes et al. with sera from three different KS patients, diluted 1:40 in master block (MB) containing PBS supplemented with 1% glycine, 2% BSA, 10% rabbit serum and 1% (wt/vol) HeLa cell sonicate. Secondary antibody FITC-conjugated F(ab′)[0072] 2 fragment of rabbit antihuman IgG (DAKO, Carpinteria, Calif.) diluted 1:40 in MB was applied. Cell nuclei were counterstained for 5 min, in PBS containing 17 μM Dapi (4′-6′-diamino-2′-phenyidole dihydrochloride [Boehringer Mannheim Corp., Indianapolis, Ind.]), rinsed in TBST, mounted with Vectashield (Vector Lab. Inc., Burlingame, Calif.) and examined in a fluorescence microscope Axioplan2 (Zeiss, Germany). BC-3 cells were run in parallel as controls.
  • FIG. 10 shows an immunofluorence assay of BC-3 cells where panel A depicts BC-3 cells stained with KS patient serum. Panel B shows BC-3 cells stained with Dapi to localize the nuclei. In panel C the BC-3 cells have been treated with [0073] glycyrrhizic acid 4 mM and stained with KS patient serum. In panel D BC-3 cells have been treated with glycyrrhizic acid 4 mM and stained with Dapi to localize the nuclei. Kaposi's Sarcoma patient serum is used primary antibody to stain the KSHV latent antigens. The treatment with glycyrrhizic acid 4 mM inhibits the expression of latent viral antigens as demonstrated in panel C. As can be seen in this panel, speckled nuclear stainings typical of positive infected cells disappears after the treatment with glycyrrhizic acid.

Claims (10)

I claim:
1. A method of treating Kaposi's sarcoma comprising the steps of
administering to the patient a therapeutic a derivative of a triterpenoid acid and wherein the triterpenoid acid has the following structural formula:
Figure US20020091158A1-20020711-C00001
 wherein:
Y═OR1, NR1 2, O--M1;
R═H, LOWER ALKYL,
M+=Na+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R4═H, OH, SO3--M1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
X═O, S, NR1 2.
2. A method of treating Kaposi's sarcoma comprising the steps of
administering to the patient a derivative of a triterpenoid acid and wherein the triterpenoid acid has the following structural formula:
Figure US20020091158A1-20020711-C00002
 wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R3═H, CH3, lower alkyl, COY, CH2OH, CH2OCH2OH=CH2, CH2OSO--3M1;
Z═NR1, NR1Ac, NR1Bz, H, OCH3, lower alkyl, OH, SO3--M1, OCH2CH═CH2, OCH2CO2 H or O-glucoside wherein a glucoside includes glucose, fucose, galactose, mannose, arabinose or xylose;
R4═H, OH, SO3--M.1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
R5 and R6═H, R1 or taken together to form a 5 or 6 membered carbocyclic ring;
X=O, S, NR1 2
W═C═O, C═CR1 2, CR1CR1 3, CR1——CR1 2OR1, COR1——CR1OR1 2, COR1CR1 2OR1, CR1CR1 2NR1 2, CR1CR1 2 OCR1COY.
3. A pharmaceutical composition for treating Kaposi's sarcoma, comprising a therapeutically effective amount of a triterpenoid acid having the following structural formula:
Figure US20020091158A1-20020711-C00003
Wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.30 , K30 , Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R4═H, OH, SO3--M1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
X=O, S, NR1 2.
4. A pharmaceutical composition for treating Kaposi's sarcoma, comprising a therapeutically effective amount of a triterpenoid acid having the following structural formula:
Figure US20020091158A1-20020711-C00004
wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R3═H, CH3, lower alkyl, COY, CH2OH, CH2OCH2CH═CH2, CH2OSO--3M1;
Z═NR1, NR1Ac, NR1Bz, H, OCH3, lower alkyl, OH, SO3--M1, OCH2CH═CH2, OCH2CO2 H or O-glucoside wherein a glucoside includes glucose, fucose, galactose, mannose, arabinose or xylose;
R4═H, OH, SO3--M.1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
R5 and R6═H,R1 or taken together to form a 5 or 6 membered carbocyclic ring;
X═O, S, NR1 2
W═C═O, C═CR1 2, CR1CR1 3, CR1——CR1 2OR1, COR1——CR1OR1 2, COR1CR1 2OR1, CR1CR1 2 NR1 2, CR1CR1 2OCR1COY.
5. A method of treating Epstein Barr virus comprising the steps of administering to the patient a therapeutic a derivative of a triterpenoid acid and wherein the triterpenoid acid has the following structural formula:
Figure US20020091158A1-20020711-C00005
 wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R4═H, OH, SO3--M1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2 R1;
or both R4 taken together are oxo;
X=O, S, NR1 2.
6. A method of treating Epstein Barr virus comprising the steps of
administering to the patient a derivative of a triterpenoid acid and wherein the triterpenoid acid has the following structural formula:
Figure US20020091158A1-20020711-C00006
 wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R3═H, CH3, lower alkyl, COY, CH2OH, CH2OCH2CH═CH2, CH2OSO--3M1;
Z═NR1, NR1Ac, NR1Bz, H, OCH3, lower alkyl, OH, SO3--M1, OCH2CH═CH2, OCH2CO2 H or O-glucoside wherein a glucoside includes glucose, fucose, galactose, mannose, arabinose or xylose;
R4═H, OH, SO3--M.1, NH(CH2)nNH2, or NH--Ph--(NH2)nwherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
R5 and R6═H, R1 or taken together to form a 5 or 6 membered carbocyclic ring;
X═O, S, NR1 2
W═C═O, C═CR1 2, CR1CR1 3, CR1——CR1 2OR1, COR1——CR1OR1 2, COR1CR1 2OR1, CR1CR1 2 NR1 2, CR1CR1 2OCR1COY.
7. A pharmaceutical composition for treating Epstein Barr virus, comprising a therapeutically effective amount of a triterpenoid acid having the following structural formula:
Figure US20020091158A1-20020711-C00007
wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R4═H, OH, SO3--M.1, NH(CH2)nNH2, or NH--Ph--(NH2)nwherein n=1-8 and is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2 R1;
or both R4 taken together are oxo;
X═O, S, NR1 2.
8. A pharmaceutical composition for treating Epstein Barr virus, comprising a therapeutically effective amount of a triterpenoid acid having the following structural formula:
Figure US20020091158A1-20020711-C00008
wherein:
Y═OR1, NR1 2, O--M1;
R1═H, LOWER ALKYL,
M1=Na.+, K+, Mg++, Ca++ ions;
R2═CH2OR1 or CH3;
R3═H, CH3, lower alkyl, COY, CH2OH, CH2OCH2CH═CH2, CH2OSO--3 M1;
Z═NR1, NR1Ac, NR1Bz, H, OCH3, lower alkyl, OH, SO3--M1, OCH2CH═CH2, OCH2CO2 H or O-glucoside wherein a glucoside includes glucose, fucose, galactose, mannose, arabinose or xylose;
R4═H, OH, SO3--M.1, NH(CH2)nNH2, or NH--Ph--(NH2)n wherein n=1-8 and Ph is a phenyl or naphthyl ring substituted with up to 3 amine functionalities and the remaining substitutions can be H, R1, R2 or CO2R1;
or both R4 taken together are oxo;
R5 and R6═H,R1 or taken together to form a 5 or 6 membered carbocyclic ring;
X═O, S, NR1 2
W═C═O, C═CR1 2, CR1CR1 3, CR1——CR1 2OR1, COR1——CR1OR1 2, COR1CR1 2OR1, CR1CR1 2NR1 2, CR1CR1 2 OCR1COY.
9. The method according to claim 1 wherein the dosage is in the range of 2.5 mg to 50 mg/kg.
10. The method according to claim 5 wherein the dosage is in the range of 2.5 mg to 50 mg/kg.
US09/976,838 1999-06-02 2001-10-15 Composition for and method of treatment using triterpenoids Abandoned US20020091158A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/976,838 US20020091158A1 (en) 1999-06-02 2001-10-15 Composition for and method of treatment using triterpenoids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/324,473 US6323183B1 (en) 1999-06-02 1999-06-02 Composition for and method of treatment using triterpenoids
US09/976,838 US20020091158A1 (en) 1999-06-02 2001-10-15 Composition for and method of treatment using triterpenoids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/324,473 Division US6323183B1 (en) 1999-06-02 1999-06-02 Composition for and method of treatment using triterpenoids

Publications (1)

Publication Number Publication Date
US20020091158A1 true US20020091158A1 (en) 2002-07-11

Family

ID=23263743

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/324,473 Expired - Fee Related US6323183B1 (en) 1999-06-02 1999-06-02 Composition for and method of treatment using triterpenoids
US09/976,838 Abandoned US20020091158A1 (en) 1999-06-02 2001-10-15 Composition for and method of treatment using triterpenoids

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/324,473 Expired - Fee Related US6323183B1 (en) 1999-06-02 1999-06-02 Composition for and method of treatment using triterpenoids

Country Status (1)

Country Link
US (2) US6323183B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1419777A1 (en) * 2002-10-29 2004-05-19 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
EP1421942A1 (en) * 2002-10-29 2004-05-26 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as RANTES inducers
US20050090428A1 (en) * 2002-01-08 2005-04-28 Emory University Porphyrins with virucidal activity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889434B (en) 2011-06-21 2017-02-15 Bvw控股公司 Medical device comprising boswellic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090428A1 (en) * 2002-01-08 2005-04-28 Emory University Porphyrins with virucidal activity
EP1419777A1 (en) * 2002-10-29 2004-05-19 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
EP1421942A1 (en) * 2002-10-29 2004-05-26 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as RANTES inducers
US20040138171A1 (en) * 2002-10-29 2004-07-15 Fujio Suzuki Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
US20040142882A1 (en) * 2002-10-29 2004-07-22 Fujio Suzuki Use of glycyrrhizin and its derivatives as RANTES inducers
US7015202B2 (en) 2002-10-29 2006-03-21 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
US20060116337A1 (en) * 2002-10-29 2006-06-01 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors

Also Published As

Publication number Publication date
US6323183B1 (en) 2001-11-27

Similar Documents

Publication Publication Date Title
EP0876387B1 (en) Use of roxithromycin for the preparation of a medicament for improving the biological and antiviral activity of protease inhibitors
Nakashima et al. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro
Hayashi et al. In vitro and in vivo antiviral activity of scopadulcic acid B from Scoparia dulcis, Scrophulariaceae, against herpes simplex virus type 1
US20070219159A1 (en) Cyclodextrin compositions and methods of treating viral infections
JPH05503073A (en) 6-Amino-1,2-benzopyrone useful in the treatment of viral diseases
TURANO et al. Inhibitory effect of papaverine on HIV replication in vitro
Perno et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages
US6323183B1 (en) Composition for and method of treatment using triterpenoids
KR100294836B1 (en) Preventive and Remedy for Viral Infections
Niu et al. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus
RU2145856C1 (en) Method of prophylaxis or inhibition of infection of t-lymphocytes with human immunodeficiency virus and replication in vivo
JP2004513092A (en) Phyllanthus-derived compounds for the prevention and / or treatment of diseases associated with nucleoside inhibitor-resistant retroviruses or non-nucleoside inhibitor-resistant retroviruses
Dianzani et al. Effects of IFNα on late stages of HIV-1 replication cycle
EP1017727B1 (en) Composition and pharmaceutical preparation containing same for the treatment of herpes and related viral infections
Cirone et al. Infection of human T lymphoid cells by human herpesvirus 6 is blocked by two unrelated protein tyrosine kinase inhibitors, biochanin A and herbimycin
IE903879A1 (en) Use of a benzodiazepine and a phenylpyrrylketone derivative
KR100341736B1 (en) Use of 2-aminopurine derivatives for the treatment and prevention of human herpesvirus 7 infection
CN117205221B (en) Application of echinochlon in preparing anti-herpesvirus medicine
US5185366A (en) Method for treatment and prevention of diseases caused by enveloped viruses, including herpes simplex virus types 1 and 2 diseases, using 3,4-dihydroxy-2H-benzopyran-2H-one
CN101557813A (en) Liposome treatment of viral infections
EP0351625A1 (en) Anti-HIV activity of BV-3608
Penney et al. Tucaresol: A Clinical Stage Oral Candidate Drug with Two Distinct Antiviral Mechanisms
HOLLAND et al. Characterization of oxyphenarsine as a potential antiviral agent for AIDS
JPH1045598A (en) Preventive and therapeutic agent for virus infectious disease
Pontani et al. Targets of amphotericin B methyl ester (AME) in the inhibition of infection of different cell lines by HIV-1

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION